GlobeNewswire Inc. · Feb 14, 2024
联拓生物宣布结束战略评估
联拓生物将开始关闭其业务，包括出售剩余资产和裁员、从纳斯达克退市以及发放特别现金股息 联拓生物将开始关闭其业务，包括出售剩余资产和裁员、从纳斯达克退市以及发放特别现金股息
LI
NASDAQ · LIAN
LianBio
Healthcare · Biotechnology
$0.32
Down-$0.03 (-8.28%)
Updated Aug 14, 2026, 7:49 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 34.47M
- P/E ratio
- 4.02
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 2.48M
- Avg. volume
- 146.63K
Price performance
LIAN price history
1M range · 0 trading sessions · Daily adjusted prices
LIAN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest LIAN news
The latest Smart Investors Daily articles mentioning LIAN.
Stock researchCompany · Overview
LIAN research
Overview
Company profile and research snapshot.
Company profile
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 3, 2024 | B of A Securities | Underperform | — |
| Dec 22, 2023 | Jefferies | Hold | — |
| Oct 25, 2023 | Raymond James | Outperform | — |
| Oct 14, 2022 | Raymond James | Outperform | — |
| Nov 26, 2021 | Jefferies | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 13, 2024
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. IPG Photonics posted GAAP earnings of 89 cents per share, versus market estimates of 95 cents per share. The company’s quarterly sales came in at $298.90 million versus expectations of $286.12 million. IPG Photonics shares dipped 11.2% to $92.06 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ohmyhome Limited (NASDAQ: OMH) shares climbed 300% to $4.80. BioNexus Gene Lab Corp. (NASDAQ: BGLC) got a boost, surging 270% to $1.52. Digital Brands Group, Inc. (NASDAQ: DBGI) shares jumped 168% to $7.69. Digital Brands reaffirmed its 2024 guidance revenue of $27 million to $30 million and commited to no equity offerings for 2024. ARB IOT Group Limited (NASDAQ: ARBB) climbed 101.8% to $3.0868 after gaining over 23% on Monday. Beamr Imaging Ltd. (NASDAQ: BMR) gained 100.7% to $19.97. Beamr Imaging priced $12 million public offering of 1,714,200 ordinary shares at $7 per share. Farmmi, Inc. (NASDAQ: FAMI) climbed 57.6% to $1.97 after surging around 10% on Monday. Whole Earth Brands, Inc. (NASDAQ: FREE) rose 35.3% to $4.75. Whole Earth Brands signed a definitive agreement to be acquired by affiliates of Sababa Holdings FREE, LLC for $4.875 per share in an all-cash transaction. VCI Global Limited (NASDAQ: VCIG) gained 27% to $1.35. Larimar Therapeutics, Inc. (NASDAQ: LRMR) climbed 25.4% to $9.82. JMP Securities analyst Jonathan Wolleben maintained Larimar Therapeutics with a Market Outperform and raised the price target from $17 to $25. Jin Medical International Ltd. (NASDAQ: ZJYL) gained 22.4% to $10.17. Tripadvisor, Inc. (NASDAQ: TRIP) shares rose 18.5% to $26.50 after the company announced it formed a Special Committee of independent members of its board of directors to evaluate proposals. LianBio (NASDAQ: LIAN) gained 17.8% to $4.76. LianBio completed strategic review and determined to initiate the wind down of its operations, including sale of remaining pipeline assets, delisting of ADSs and workforce reductions. Verde Clean Fuels, Inc. (NASDAQ: VGAS) gained 17.8% to $3.2997. Verde Clean Fuels, Inc. and Diamondback Energy subsidiary Cottonmouth Ventures LLC announced joint development agreement for a proposed natural gas-to-gasoline facility in Permian Basin. JetBlue Airways Corporation (NASDAQ: JBLU) shares surged 13.5% to $6.89 after Carl Icahn disclosed a ...
GlobeNewswire Inc. · Feb 13, 2024
LianBio Announces Completion of Strategic Review
LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of special cash dividend LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of special cash dividend
Benzinga · Jan 3, 2024
B of A Securities Downgrades LianBio: Here's What You Need To Know
B of A Securities downgraded its rating of LianBio (NASDAQ:LIAN) to Underperform with a price target of $3.00, changing its price target from $5.00 to $3.00. Shares of LianBio are trading down 1.83% over the last 24 hours, at $4.29 per share. A move to $3.00 would account for a 30.07% decrease from the current share price. About LianBio LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically ...Full story available on Benzinga.com
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
